Quality of LifeGluColNCT07229014
Effects of a Collagen Supplement on Quality of Life, Appetite and Glycaemic Control
A study testing Collagen peptide supplement in people with Quality of Life and Appetite, run by King's College London at 1 site in United Kingdom.
Trial summary
This is a clinical trial aimed to investigate if a collagen supplement can improve quality of life, appetite and blood sugar in overweight and obese adults aged 18-65. Hypothesis: Consumption of a collagen supplement for 8 days will improve quality of life and improve glycaemic control in comparison with a placebo in… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Quality of Life, Appetite, Sleep
- What is being tested?
- Collagen peptide supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Dec 2025to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subject is a healthy (as assessed by medical history) male or female adult, aged 18-65 years and overweight or obese (BMI 25 - 40 kg/m2).
- Subject has an impaired quality of life, as determined by scoring at least a total of 9 on the following questions:
- In the past 4 weeks, did you feel you had a lot of energy? All of the time (1), most of the time (2), a good bit of the time (3), some of the time (4), a little of the time (5), and none of the time (6) (number 27 from SF-36 questionnaire) Version 3.0 [01/10/2025] Page 11 of 20
- In the past 4 weeks, have you felt calm and peaceful? All of the time (1), most of the time (2), a good bit of the time (3), some of the time (4), a little of the time (5), and none of the time (6) (number 26 from SF-36 questionnaire)
- In the past 2 weeks, did you have any difficulties with sleeping? Not at all (1), small amounts (2), moderate amounts (3), a great deal (4), an extreme amount (5), all the time (6) (number 3 from WHOQoL-100)
- Participant has an email address, internet access, a compatible smartphone and is willing and able to maintain internet access throughout the trial to complete virtual visits via video conference and to engage with mobile apps to answer electronic questionnaires.
Show all 9Show fewer
- Subject is willing and able to comply with all study procedures, including consumption of the supplement daily, CGM use for 22 days total (2 x 11 days), complete standardised meal tests, and fill out health questionnaires.
- Subject is willing to take a supplement of bovine animal origin.
- Openness to participate in an online interview at the end of the study.
Who cannot join
- Participant has a history or presence of uncontrolled and/or clinically important pulmonary, cardiac, hepatic, renal, endocrine (including type 1 and 2 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and/or anxiety disorders) or biliary disorders.
- Participant has a clinically important gastrointestinal (GI) condition that would potentially interfere with the evaluation of the study product [e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the investigator), history of frequent diarrhoea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the investigator, medication managed reflux and/or clinically important lactose intolerance.
- Participant has a history of chronic insomnia (defined as insomnia at least 3 d/week over the past month), a diagnosed sleep disorder (e.g., OSA), or a chronic medical condition that may impact energy/fatigue levels, in the judgment of the investigator.
- Participant is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded.
- Participant has a known allergy, intolerance, or sensitivity to any of the ingredients in the study product, including bovine animal products.
- Participant has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
Show all 12Show fewer
- Participant has experienced any major trauma or any other surgical event within three months of Virtual Visit 1.
- Participant has unstable use of a medication or supplement that the investigator considers may affect the outcomes of the trial.
- Participant is currently in another biomedical research study or has been in the 30 days before screening.
- Participant is an employee of, or has a financial interest in Darling Ingredients Inc.
- The individual has a condition the investigator believes would interfere with his ability to provide informed consent and to comply with the study protocol, which might confound the interpretation of the study results, or put the participant at undue risk.
- Participant is a vegan or vegetarian or excludes bovine products for cultural or religious reasons.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ana Rodriguez-Mateos, PhD contact
United Kingdom1 site, 1 recruiting
- Recruiting
Metabolic Research Unit (KCL, Waterloo Campus)
London, London, SE1 9NH
Alex Cheok, PhD, +442078484162, glucol@kcl.ac.uk
Alex Cheok, PhD
About this study
Official title: Effects of a Collagen Supplement on Quality of Life, Appetite and Glycaemic Control: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial in Overweight and Obese Adults.
This is a clinical trial aimed to investigate if a collagen supplement can improve quality of life, appetite and blood sugar in overweight and obese adults aged 18-65.
Hypothesis: Consumption of a collagen supplement for 8 days will improve quality of life and improve glycaemic control in comparison with a placebo in individuals overweight or with obesity with a perceived low quality of life.
Participants will be asked to:
- Consume a collagen peptide supplement for a total of 8 days at a time
- Fill in questionnaires about quality of life, appetite, mood and energy
- Wear continuous glucose monitors
- Conditions
- Quality of Life, Appetite, Sleep, Mood, Energy, Blood Glucose Profile
- Being tested
- Collagen peptide supplement, Placebo
- Keywords
- collagen, glucose, appetite, statiety, mood, sleep
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collagen peptide supplementDietary supplement
5 g of hydrolysed collagen peptide of bovine origin in powdered form. Taken twice daily for 8 days total.
PlaceboOther
5 g of maltodextrin in powdered form. Taken twice daily for 8 days total.
| Study group | Role | What they receive |
|---|---|---|
| Collagen peptide then placebo | Experimental | 2 x 5g of hydrolysed collagen peptide daily for 8 days then crossing over to the placebo Receives: Dietary Supplement: Collagen peptide supplement; Other: Placebo |
| Placebo then collagen peptide | Experimental | 2 x 5g of maltodextrin daily for 8 days then crossing over to the collagen peptide Receives: Dietary Supplement: Collagen peptide supplement; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of life scores
Quality of life (QoL) scores based on the composite scoring of the 36-item Short Form Survey (SF-36)
Measured: Baseline and 8 days
Secondary outcomes (7)
Postprandial appetite, hunger, fullness, satiety or desire to eat
Postprandial appetite (hunger, fullness, satiety or desire to eat), energy and mood after consumption of a standardised challenge meal, measured using a digital visual analogue scale (VAS)
Measured: 15, 30, 60, 120 and 180 minutes post-meal
Mood
Mood measured using the Positive and Negative Affect Schedule Short Form (PANAS-SF) for positive affects (PA), negative affects (NA) and affect balance scores.
Measured: Baseline and 7 days
Energy and fatigue
Energy and fatigue measured using the Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) for fatigue, energy and overall scores
Measured: Baseline and 7 days
Sleep
Sleep measured with the Pittsburgh Sleep Quality Index (PSQI) for Global PSQI score and component scores of sleep quality, latency, duration, efficiency, disturbances and daytime dysfunction.
Measured: Baseline and 8 days
Glycaemic variability
Glycaemic variability, including overall mean blood glucose, fasting blood glucose, daytime mean blood glucose, daytime glucose variability (CV), % time within range and number of hypoglycaemic events, measured via a continuous glucose monitor (CGM)
Measured: From baseline to 8 days
Postprandial glucose response
Postprandial glucose response to a standardised breakfast expressed in difference in glucose Cmax, glucose Cmin, glucose Tmax, glucose Tmin and area under the curve, measured using continuous glucose monitor (CGM)
Measured: Continous monitoring up to 5 hours post-meal
Habitual diet
Habitual diet assessed via the European Prospective Investigation into Cancer and Nutrition (EPIC) food frequency questionnaire (FFQ)
Measured: Baseline only
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2025
- Study startDec 2025 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Quality of LifeStudies of the same condition, open and under way.
- More trials run by King's College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- Rousselot BVBA
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07229014
- Sponsor's protocol ID
- GluCol Study
- Acronym
- GluCol
- Status last verified
- Oct 2025
- First submitted
- 13 Nov 2025
- Last updated
- 14 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of a Collagen Supplement on Quality of Life, Appetite and Glycaemic Control: a Randomised, Double-blinded, Placebo-controlled, Crossover Trial in Overweight and Obese Adults.
- ClinicalTrials.gov ID
- NCT07229014
- Acronym / sponsor ID
- GluCol / GluCol Study
- Conditions
- Quality of Life, Appetite, Sleep, Mood, Energy, Blood Glucose Profile
- Keywords
- collagen, glucose, appetite, statiety, mood, sleep
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- Rousselot BVBA
- Study start
- Dec 2025 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 14 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a clinical trial aimed to investigate if a collagen supplement can improve quality of life, appetite and blood sugar in overweight and obese adults aged 18-65.
Hypothesis: Consumption of a collagen supplement for 8 days will improve quality of life and improve glycaemic control in comparison with a placebo in individuals overweight or with obesity with a perceived low quality of life.
Participants will be asked to:
- Consume a collagen peptide supplement for a total of 8 days at a time
- Fill in questionnaires about quality of life, appetite, mood and energy
- Wear continuous glucose monitors
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Collagen peptide then placebo | Experimental | Dietary Supplement: Collagen peptide supplement, Other: Placebo2 x 5g of hydrolysed collagen peptide daily for 8 days then crossing over to the placebo |
| Placebo then collagen peptide | Experimental | Dietary Supplement: Collagen peptide supplement, Other: Placebo2 x 5g of maltodextrin daily for 8 days then crossing over to the collagen peptide |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Subject is a healthy (as assessed by medical history) male or female adult, aged 18-65 years and overweight or obese (BMI 25 - 40 kg/m2).
- Subject has an impaired quality of life, as determined by scoring at least a total of 9 on the following questions:
- Participant has an email address, internet access, a compatible smartphone and is willing and able to maintain internet access throughout the trial to complete virtual visits via video conference and to engage with mobile apps to answer electronic questionnaires.
- Subject is willing and able to comply with all study procedures, including consumption of the supplement daily, CGM use for 22 days total (2 x 11 days), complete standardised meal tests, and fill out health questionnaires.
- Subject is willing to take a supplement of bovine animal origin.
Key exclusion criteria (12 listed)
- Participant has a history or presence of uncontrolled and/or clinically important pulmonary, cardiac, hepatic, renal, endocrine (including type 1 and 2 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and/or anxiety disorders) or biliary disorders.
- Participant has a clinically important gastrointestinal (GI) condition that would potentially interfere with the evaluation of the study product [e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the investigator), history of frequent diarrhoea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the investigator, medication managed reflux and/or clinically important lactose intolerance.
- Participant has a history of chronic insomnia (defined as insomnia at least 3 d/week over the past month), a diagnosed sleep disorder (e.g., OSA), or a chronic medical condition that may impact energy/fatigue levels, in the judgment of the investigator.
- Participant is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded.
- Participant has a known allergy, intolerance, or sensitivity to any of the ingredients in the study product, including bovine animal products.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collagen peptide supplement5 g of hydrolysed collagen peptide of bovine origin in powdered form. Taken twice daily for 8 days total. | Dietary supplement | Collagen peptide then placebo, Placebo then collagen peptide |
| Placebo5 g of maltodextrin in powdered form. Taken twice daily for 8 days total. | Other | Collagen peptide then placebo, Placebo then collagen peptide |
Primary outcome
Quality of life scores
Time frame: Baseline and 8 days
Quality of life (QoL) scores based on the composite scoring of the 36-item Short Form Survey (SF-36)
7 secondary outcomes
Postprandial appetite, hunger, fullness, satiety or desire to eat
Time frame: 15, 30, 60, 120 and 180 minutes post-meal
Mood
Time frame: Baseline and 7 days
Energy and fatigue
Time frame: Baseline and 7 days
Sleep
Time frame: Baseline and 8 days
Glycaemic variability
Time frame: From baseline to 8 days
Postprandial glucose response
Time frame: Continous monitoring up to 5 hours post-meal
Habitual diet
Time frame: Baseline only
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Quality of Life
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
Cancer, Survivorship
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ana Rodriguez-Mateos, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collagen peptide supplement in people with Quality of Life and Appetite, run by King's College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alex Cheok, PhD (+442078480313 ext. 80313, alex.cheok@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of life scores (time frame: Baseline and 8 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2025.